Low- vs. Middle-dose Total Skin Electron Beam Therapy for Mycosis Fungoides: An Efficiency-based Retrospective Survey of Skin Response

Optimal doses of total skin electron beam therapy for mycosis fungoides remain to be established. Clinical efficiency and adverse effects of middle-dose (25 Gy) vs. low-dose (10-12 Gy) total skin electron beam therapy were retrospectively compared in a series of 14 and 12 mycosis fungoides, respecti...

Full description

Saved in:
Bibliographic Details
Published inActa dermato-venereologica Vol. 99; no. 6; pp. 544 - 550
Main Authors Taverniers, Annelies, Du-Thanh, Aurélie, Charissoux, Marie, Kerr, Christine, Dereure, Olivier
Format Journal Article
LanguageEnglish
Published Sweden Society for Publication of Acta Dermato-Venereologica 01.05.2019
Medical Journals Sweden
Subjects
Adult
Aged
Aged, 80 and over
Disease-Free Survival
Electrons - adverse effects
Electrons - therapeutic use
Female
Humans
Life Sciences
low dose
Male
Middle Aged
middle dose
mycosis fungoides
Mycosis Fungoides - pathology
Mycosis Fungoides - radiotherapy
Neoplasm Recurrence, Local - pathology
Neoplasm Staging
Radiotherapy Dosage
Retrospective Studies
Skin Neoplasms - pathology
Skin Neoplasms - radiotherapy
total skin electron beam therapy
Treatment Outcome
middle dose
low dose
total skin electron beam therapy
mycosis fungoides
Online AccessGet full text

Cover

More Information
Summary:Optimal doses of total skin electron beam therapy for mycosis fungoides remain to be established. Clinical efficiency and adverse effects of middle-dose (25 Gy) vs. low-dose (10-12 Gy) total skin electron beam therapy were retrospectively compared in a series of 14 and 12 mycosis fungoides, respectively. Overall skin response rate was 96.2% (92.9% middle-dose and 100% low-dose; not significant (NS)). Overall complete and partial skin response rates were 57.7% (42.9% middle-dose and 75% low-dose; NS) and 38.5% (50% middle-dose and 25% low-dose; NS), respectively. All responding patients relapsed after an overall median time of 5 months (7 months middle-dose vs. 4 months low-dose; p = 0.164, NS). Tolerance was equally fair in both groups, with only grade 1 and 2 adverse events observed in 100% vs. 66.7% of patients in middle-dose and low-dose groups (NS). Although no significant difference was observed, middle-dose protocol may be recommended owing to a longer relapse-free survival for a similar tolerance.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0001-5555
1651-2057
DOI:10.2340/00015555-3124